Terms: = Germ cell tumor AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
899 results:
1. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
[TBL] [Abstract] [Full Text] [Related]
2. Oncolytic herpes simplex virus expressing il-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract] [Full Text] [Related]
3. Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?
Fishman J; Buchbinder EI
Cancer J; 2024 Mar-Apr 01; 30(2):120-125. PubMed ID: 38527266
[TBL] [Abstract] [Full Text] [Related]
4. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract] [Full Text] [Related]
5. Pimecrolimus protects neuron-like SH-SY5Y cells against anti-inflammatory and anti-oxidant effects of both microglial secretome and hydrogen peroxide.
Kocanci FG; Erol AYG; Yildiz F; Eciroglu H
Scand J Immunol; 2024 Jan; 99(1):e13328. PubMed ID: 38441277
[TBL] [Abstract] [Full Text] [Related]
6. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
Betof Warner A; Hamid O; Komanduri K; Amaria R; Butler MO; Haanen J; Nikiforow S; Puzanov I; Sarnaik A; Bishop MR; Schoenfeld AJ
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38423748
[TBL] [Abstract] [Full Text] [Related]
7. Mouse Melanoma Model in tumor Vaccines and Immunotherapy Research.
De Robertis M; Lampreht Tratar U; Signori E; Komel T; Čemažar M
Methods Mol Biol; 2024; 2773():157-163. PubMed ID: 38236544
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy against Lung Cancer Is Augmented by Combining Aberrantly N-Glycosylated T cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.
Toyofuku T; Ishikawa T; Nojima S; Kumanogoh A
J Immunol; 2024 Mar; 212(5):917-927. PubMed ID: 38214607
[TBL] [Abstract] [Full Text] [Related]
9. NK cells propagate T cell immunity following in situ tumor vaccination.
Jin WJ; Jagodinsky JC; Vera JM; Clark PA; Zuleger CL; Erbe AK; Ong IM; Le T; Tetreault K; Berg T; Rakhmilevich AL; Kim K; Newton MA; Albertini MR; Sondel PM; Morris ZS
Cell Rep; 2023 Dec; 42(12):113556. PubMed ID: 38096050
[TBL] [Abstract] [Full Text] [Related]
10. Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
Kim HE; Kim J; Park HK; Lee JB; Yun SJ
Melanoma Res; 2024 Feb; 34(1):38-43. PubMed ID: 37924528
[TBL] [Abstract] [Full Text] [Related]
11. tumor-infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer.
Jacover A; Zarbiv Y; Tal KH; Klein S; Breuer S; Durst R; Avni B; Grisariu S; Stepensky P; Lotem M; Maimon O; Yablonski-Peretz T
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1894. PubMed ID: 37750497
[TBL] [Abstract] [Full Text] [Related]
12. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Diab A; Gogas H; Sandhu S; Long GV; Ascierto PA; Larkin J; Sznol M; Franke F; Ciuleanu TE; Pereira C; Muñoz Couselo E; Bronzon Damian F; Schenker M; Perfetti A; Lebbe C; Quéreux G; Meier F; Curti BD; Rojas C; Arriaga Y; Yang H; Zhou M; Ravimohan S; Statkevich P; Tagliaferri MA; Khushalani NI
J Clin Oncol; 2023 Oct; 41(30):4756-4767. PubMed ID: 37651676
[TBL] [Abstract] [Full Text] [Related]
13. TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
Tvingsholm SA; Frej MS; Rafa VM; Hansen UK; Ormhøj M; Tyron A; Jensen AWP; Kadivar M; Bentzen AK; Munk KK; Aasbjerg GN; Ternander JSH; Heeke C; Tamhane T; Schmess C; Funt SA; Kjeldsen JW; Kverneland AH; Met Ö; Draghi A; Jakobsen SN; Donia M; Marie Svane I; Hadrup SR
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586765
[TBL] [Abstract] [Full Text] [Related]
14. T cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma cell Lines.
Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH
Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142
[TBL] [Abstract] [Full Text] [Related]
15. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies.
Ou L; Liu S; Wang H; Guo Y; Guan L; Shen L; Luo R; Elder DE; Huang AC; Karakousis G; Miura J; Mitchell T; Schuchter L; Amaravadi R; Flowers A; Mou H; Yi F; Guo W; Ko J; Chen Q; Tian B; Herlyn M; Xu X
EBioMedicine; 2023 Jun; 92():104614. PubMed ID: 37229906
[TBL] [Abstract] [Full Text] [Related]
16. Immunity and reproduction protective effects of Chitosan Oligosaccharides in Cyclophosphamide/Busulfan-induced premature ovarian failure model mice.
Li X; Ye H; Su T; Hu C; Huang Y; Fu X; Zhong Z; Du X; Zheng Y
Front Immunol; 2023; 14():1185921. PubMed ID: 37228612
[TBL] [Abstract] [Full Text] [Related]
17. Rethinking Oncologic treatment Strategies with Interleukin-2.
Ko B; Takebe N; Andrews O; Makena MR; Chen AP
Cells; 2023 May; 12(9):. PubMed ID: 37174716
[TBL] [Abstract] [Full Text] [Related]
18. Computational systems biology approach for permanent tumor elimination and normal tissue protection using negative biasing: Experimental validation in malignant melanoma as case study.
Kumari B; Sakode C; Lakshminarayanan R; Roy PK
Math Biosci Eng; 2023 Mar; 20(5):9572-9606. PubMed ID: 37161256
[TBL] [Abstract] [Full Text] [Related]
19. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
[TBL] [Abstract] [Full Text] [Related]
20. Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.
Cui C; Chen Y; Luo Z; Zou Z; Jiang Y; Pan H; Fan Q; Zhao J; Xu Q; Jiang R; Wang X; Ma T; Guo Z; Si L; Chi Z; Sheng X; Dou Y; Tan Q; Wu D; Guo J
BMC Cancer; 2023 Feb; 23(1):121. PubMed ID: 36747118
[TBL] [Abstract] [Full Text] [Related]
[Next]